Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

[Paclitaxel containing chemotherapeutic regimens in first line and reintroduced palliative treatment of metastatic cervical cancer].

Kullmann T, Sipőcz I, Agyemang-Prempeh K, Barna O, Pintér T.

Orv Hetil. 2018 Jun;159(24):974-977. doi: 10.1556/650.2018.31062. Hungarian.

PMID:
29888659
2.

[Stereotactic body radiotherapy of liver metastasis: early experience].

Földi G, Polgár C, Zongor Z, Melles-Bencsik B, Stelczer G, Madaras B, Pintér T, Jederán É, Lövey J.

Magy Onkol. 2018 Mar 23;62(1):62-67. Epub 2018 Jan 31. Hungarian.

3.

Development of a Rubredoxin-Type Center Embedded in a de Dovo-Designed Three-Helix Bundle.

Tebo AG, Pinter TBJ, García-Serres R, Speelman AL, Tard C, Sénéque O, Blondin G, Latour JM, Penner-Hahn J, Lehnert N, Pecoraro VL.

Biochemistry. 2018 Apr 24;57(16):2308-2316. doi: 10.1021/acs.biochem.8b00091. Epub 2018 Apr 9.

4.

Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity.

Tornyos A, Aradi D, Horváth IG, Kónyi A, Magyari B, Pintér T, Vorobcsuk A, Tornyos D, Komócsi A.

PLoS One. 2017 Dec 7;12(12):e0188493. doi: 10.1371/journal.pone.0188493. eCollection 2017.

5.

Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.

Rubovszky G, Budai B, Ganofszky E, Horváth Z, Juhos É, Madaras B, Nagy T, Szabó E, Pintér T, Tóth E, Nagy P, Láng I, Hitre E.

Pathol Oncol Res. 2018 Apr;24(2):237-244. doi: 10.1007/s12253-017-0238-y. Epub 2017 Apr 29.

PMID:
28456898
6.

[Does the sidedness determine the first line treatment of irresectable metastatic colorectal cancer?]

Kullmann T, Sipőcz I, Pintér T.

Orv Hetil. 2017 Mar;158(9):340-344. doi: 10.1556/650.2017.30682. Hungarian.

PMID:
28245681
7.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).

Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P, Hotko Y, Jassem J, Kurteva G, Novotny J, O'Reilly S, Salek T, Reiner M, Morrow PK, Choi MR, Whittaker S, Blanke C.

Clin Colorectal Cancer. 2017 Jun;16(2):103-114.e3. doi: 10.1016/j.clcc.2016.08.008. Epub 2016 Sep 7.

PMID:
28038865
8.

[Effective systemic palliative chemotherapy for intracranial metastases of breast cancer].

Sipőcz I, Pintér T, Skaliczky Z, Kullmann T.

Orv Hetil. 2016 Nov;157(45):1809-1813. Hungarian.

PMID:
27817234
9.

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S, Kim ST, Huang X, Schnell P, Nadanaciva S, Bartlett CH, Slamon DJ.

Breast Cancer Res. 2016 Jun 28;18(1):67. doi: 10.1186/s13058-016-0721-5.

10.

[Effective palliative chemotherapy in a patient with collecting duct carcinoma of a unilateral kidney associated with anuria. Case report].

Kullmann T, Pintér T, Szepesvári Z, Kránitz N, Culine S.

Orv Hetil. 2016 Mar 13;157(11):436-9. doi: 10.1556/650.2016.30387. Hungarian.

PMID:
26947093
11.

Defining the metal binding pathways of human metallothionein 1a: balancing zinc availability and cadmium seclusion.

Irvine GW, Pinter TB, Stillman MJ.

Metallomics. 2016 Jan;8(1):71-81. doi: 10.1039/c5mt00225g.

PMID:
26583802
12.

A Heme-responsive Regulator Controls Synthesis of Staphyloferrin B in Staphylococcus aureus.

Laakso HA, Marolda CL, Pinter TB, Stillman MJ, Heinrichs DE.

J Biol Chem. 2016 Jan 1;291(1):29-40. doi: 10.1074/jbc.M115.696625. Epub 2015 Nov 3.

13.

Putting the pieces into place: Properties of intact zinc metallothionein 1A determined from interaction of its isolated domains with carbonic anhydrase.

Pinter TB, Stillman MJ.

Biochem J. 2015 Nov 1;471(3):347-56. doi: 10.1042/BJ20150676. Epub 2015 Aug 20.

PMID:
26475450
14.

Kinetics of Zinc and Cadmium Exchanges between Metallothionein and Carbonic Anhydrase.

Pinter TB, Stillman MJ.

Biochemistry. 2015 Oct 13;54(40):6284-93. doi: 10.1021/acs.biochem.5b00912. Epub 2015 Oct 1.

PMID:
26401817
15.

[New option in the management of cancer pain in Hungary: short acting oral opioid therapy].

Kullmann T, Sipőcz I, Csikós Á, Pintér T.

Orv Hetil. 2015 Jun 21;156(25):1003-6. doi: 10.1556/650.2015.30171. Review. Hungarian.

PMID:
26170088
16.

Domain Selection in Metallothionein 1A: Affinity-Controlled Mechanisms of Zinc Binding and Cadmium Exchange.

Pinter TB, Irvine GW, Stillman MJ.

Biochemistry. 2015 Aug 18;54(32):5006-16. doi: 10.1021/acs.biochem.5b00452. Epub 2015 Aug 4.

PMID:
26167879
17.

The effect of food environments on fruit and vegetable intake as modified by time spent at home: a cross-sectional study.

Chum A, Farrell E, Vaivada T, Labetski A, Bohnert A, Selvaratnam I, Larsen K, Pinter T, O'Campo P.

BMJ Open. 2015 Jun 4;5(6):e006200. doi: 10.1136/bmjopen-2014-006200.

18.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ.

Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.

PMID:
25524798
19.

The zinc balance: competitive zinc metalation of carbonic anhydrase and metallothionein 1A.

Pinter TB, Stillman MJ.

Biochemistry. 2014 Oct 7;53(39):6276-85. doi: 10.1021/bi5008673. Epub 2014 Sep 26.

PMID:
25208334
20.

Meta-analysis of randomized trials on access site selection for percutaneous coronary intervention in ST-segment elevation myocardial infarction.

Komócsi A, Aradi D, Kehl D, Ungi I, Thury A, Pintér T, Di Nicolantonio JJ, Tornyos A, Vorobcsuk A.

Arch Med Sci. 2014 May 12;10(2):203-12. doi: 10.5114/aoms.2014.42570. Epub 2014 May 13. Review.

21.

Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.

Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A.

J Am Coll Cardiol. 2014 Mar 25;63(11):1061-70. doi: 10.1016/j.jacc.2013.12.023. Epub 2014 Jan 30.

22.

Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.

Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ; Translational Research in Oncology BCIRG 006 Trial Investigators.

Oncologist. 2013;18(7):812-8. doi: 10.1634/theoncologist.2013-0091. Epub 2013 Jun 28.

23.

Dissecting the complex recognition interfaces of potent tetrazole- and pyrrole-based anion binders.

Pinter T, Simhadri C, Hof F.

J Org Chem. 2013 May 17;78(10):4642-8. doi: 10.1021/jo400372c. Epub 2013 May 3.

PMID:
23631741
24.

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.

Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J.

J Clin Oncol. 2013 Apr 20;31(12):1554-61. doi: 10.1200/JCO.2012.46.4057. Epub 2013 Mar 11.

25.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; TRIO/BCIRG 001 investigators.

Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012 Dec 12.

PMID:
23246022
26.

Soluble diamagnetic model for malaria pigment: coordination chemistry of gallium(III)protoporphyrin-IX.

Bohle DS, Dodd EL, Pinter TB, Stillman MJ.

Inorg Chem. 2012 Oct 15;51(20):10747-61. doi: 10.1021/ic301106g. Epub 2012 Oct 2.

PMID:
23030718
27.

Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).

Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP.

J Clin Oncol. 2012 Oct 10;30(29):3596-603. doi: 10.1200/JCO.2012.42.6031. Epub 2012 Sep 10.

PMID:
22965965
28.

Insight into blocking heme transfer by exploiting molecular interactions in the core Isd heme transporters IsdA-NEAT, IsdC-NEAT, and IsdE of Staphylococcus aureus.

Tiedemann MT, Pinter TB, Stillman MJ.

Metallomics. 2012 Aug;4(8):751-60. doi: 10.1039/c2mt20067h. Epub 2012 Jul 11.

PMID:
22786442
29.
30.

Spectroscopic and theoretical studies of Ga(III)protoporphyrin-IX and its reactions with myoglobin.

Pinter TB, Dodd EL, Bohle DS, Stillman MJ.

Inorg Chem. 2012 Mar 19;51(6):3743-53. doi: 10.1021/ic202731g. Epub 2012 Feb 28.

PMID:
22372462
31.

The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies.

Komócsi A, Vorobcsuk A, Faludi R, Pintér T, Lenkey Z, Költo G, Czirják L.

Rheumatology (Oxford). 2012 Jun;51(6):1027-36. doi: 10.1093/rheumatology/ker357. Epub 2012 Jan 5. Review.

PMID:
22223705
32.

Just add tetrazole: 5-(2-pyrrolo)tetrazoles are simple, highly potent anion recognition elements.

Courtemanche RJ, Pinter T, Hof F.

Chem Commun (Camb). 2011 Dec 21;47(47):12688-90. doi: 10.1039/c1cc15875a. Epub 2011 Oct 31.

PMID:
22038194
33.

Adjuvant trastuzumab in HER2-positive breast cancer.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group.

N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.

34.

Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.

Aradi D, Rideg O, Vorobcsuk A, Magyarlaki T, Magyari B, Kónyi A, Pintér T, Horváth IG, Komócsi A.

Eur J Clin Invest. 2012 Apr;42(4):384-92. doi: 10.1111/j.1365-2362.2011.02594.x. Epub 2011 Sep 9.

PMID:
21902692
35.

[Cardiorenal syndromes].

Késöi I, Sági B, Vas T, Pintér T, Kovács T, Wittmann I, Nagy J.

Orv Hetil. 2011 Sep 18;152(38):1520-7. doi: 10.1556/OH.2011.29212. Review. Hungarian.

PMID:
21896443
36.

Different effect of IgA nephropathy and polycystic kidney disease on arterial stiffness.

Késoi I, Sági B, Tóth OI, Vas T, Fazekas A, Kovács T, Pintér T, Wittmann I, Nagy J.

Kidney Blood Press Res. 2011;34(3):158-66. doi: 10.1159/000326802. Epub 2011 Apr 7.

37.

Recognition properties of carboxylic acid bioisosteres: anion binding by tetrazoles, aryl sulfonamides, and acyl sulfonamides on a calix[4]arene scaffold.

Pinter T, Jana S, Courtemanche RJ, Hof F.

J Org Chem. 2011 May 20;76(10):3733-41. doi: 10.1021/jo200031u. Epub 2011 Apr 18.

PMID:
21462934
38.

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiełło-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroose R, Hurvitz S, Baños A, Adewoye H, Hei YJ, Lindsay MA, Rupin M, Cabaribere D, Lemmerick Y, Mackey JR; TRIO 010 investigators.

Lancet Oncol. 2011 Apr;12(4):369-76. doi: 10.1016/S1470-2045(11)70037-7. Epub 2011 Mar 21. Erratum in: Lancet Oncol. 2011 Aug;12(8):722.

PMID:
21429799
39.

Mechanism of coronary flow reserve reduction in systemic sclerosis: insight from intracoronary pressure wire studies.

Pintér T, Faludi R, Magyari B, Vorobcsuk A, Kumánovics G, Minier T, Czirják L, Komócsi A.

Rheumatology (Oxford). 2011 Apr;50(4):781-8. doi: 10.1093/rheumatology/keq402. Epub 2010 Dec 13.

PMID:
21156672
40.

[Pharmaceutical therapy of breast cancer].

Láng I, Kahán Z, Pintér T, Dank M, Boér K, Pajkos G, Faluhelyi Z, Pikó B, Eckhardt S, Horváth Z.

Magy Onkol. 2010 Sep;54(3):237-54. doi: 10.1556/MOnkol.54.2010.3.5. Hungarian. No abstract available.

41.

Inscribing the perimeter of the PagP hydrocarbon ruler by site-specific chemical alkylation.

Khan MA, Moktar J, Mott PJ, Vu M, McKie AH, Pinter T, Hof F, Bishop RE.

Biochemistry. 2010 Oct 26;49(42):9046-57. doi: 10.1021/bi1011496.

42.

Arsenic-metalation of triple-domain human metallothioneins: Support for the evolutionary advantage and interdomain metalation of multiple-metal-binding domains.

Ngu TT, Lee JA, Pinter TB, Stillman MJ.

J Inorg Biochem. 2010 Mar;104(3):232-44. doi: 10.1016/j.jinorgbio.2009.12.007. Epub 2009 Dec 13.

PMID:
20079542
43.
44.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.

N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.

45.

Development of a concise and general enantioselective approach to 2,5-disubstituted-3-hydroxytetrahydrofurans.

Kang B, Mowat J, Pinter T, Britton R.

Org Lett. 2009 Apr 16;11(8):1717-20. doi: 10.1021/ol802711s.

PMID:
19323544
46.

Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis.

Komócsi A, Pintér T, Faludi R, Magyari B, Bozó J, Kumánovics G, Minier T, Radics J, Czirják L.

Ann Rheum Dis. 2010 Jan;69(1):202-5. doi: 10.1136/ard.2008.096255.

PMID:
19158116
47.

Thienopyridine therapy influences late outcome after coronary stent implantation.

Aradi D, Kónyi A, Pálinkás L, Berki T, Pintér T, Tahin T, Horváth I, Papp L, Komócsi A.

Angiology. 2008 Apr-May;59(2):172-8. doi: 10.1177/0003319707304572. Epub 2008 Apr 2.

PMID:
18388039
48.

Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.

Bastit L, Vandebroek A, Altintas S, Gaede B, Pintér T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF.

J Clin Oncol. 2008 Apr 1;26(10):1611-8. doi: 10.1200/JCO.2006.10.4620.

PMID:
18375890
49.

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

Smith RE Jr, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA.

J Clin Oncol. 2008 Mar 1;26(7):1040-50. doi: 10.1200/JCO.2007.14.2885. Epub 2008 Jan 28.

PMID:
18227526
50.

Magnetic resonance studies in management of adult cases with Bland-White-Garland syndrome.

Komócsi A, Simor T, Tóth L, Szabados S, Mágel F, Pintér T, Aradi D, Kónyi A, Horváth IG, Papp L.

Int J Cardiol. 2007 Dec 15;123(1):e8-11. Epub 2007 Feb 15.

PMID:
17306388

Supplemental Content

Loading ...
Support Center